Focus Partners Advisor Solutions LLC Sells 1,744 Shares of Eli Lilly and Company (NYSE:LLY)

Focus Partners Advisor Solutions LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 12.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,135 shares of the company's stock after selling 1,744 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Eli Lilly and Company were worth $9,369,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Kolinsky Wealth Management LLC raised its position in Eli Lilly and Company by 3.3% during the fourth quarter. Kolinsky Wealth Management LLC now owns 439 shares of the company's stock valued at $339,000 after acquiring an additional 14 shares in the last quarter. Continuum Advisory LLC raised its position in Eli Lilly and Company by 6.2% during the fourth quarter. Continuum Advisory LLC now owns 1,594 shares of the company's stock valued at $1,230,000 after acquiring an additional 93 shares in the last quarter. NCM Capital Management LLC raised its position in shares of Eli Lilly and Company by 37.2% in the fourth quarter. NCM Capital Management LLC now owns 2,786 shares of the company's stock valued at $2,151,000 after purchasing an additional 756 shares during the period. Royal Capital Wealth Management LLC raised its position in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Royal Capital Wealth Management LLC now owns 3,634 shares of the company's stock valued at $2,805,000 after purchasing an additional 15 shares during the period. Finally, Glen Eagle Advisors LLC raised its position in shares of Eli Lilly and Company by 0.6% in the fourth quarter. Glen Eagle Advisors LLC now owns 3,499 shares of the company's stock valued at $2,701,000 after purchasing an additional 20 shares during the period. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on LLY shares. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $745.72 on Wednesday. The stock's 50 day moving average is $795.44 and its 200-day moving average is $804.82. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a market capitalization of $706.75 billion, a price-to-earnings ratio of 63.68, a PEG ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.58 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.80%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.